AMRN logo

Amarin Corporation plc

AMRN
Healthcare|Drug Manufacturers - General|IE
$11.61
+0.04 (+0.30%)
Tangible Book / Share
$20.79
Cash / Share
$15.53

About

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

Stock Price

-25.9%(1Y)
1M
-3.2%
3M
-19.2%
6M
-22.9%
YTD
-16.8%
1Y
-26.8%
3Y
-23.2%
5Y
-86.0%

Pipeline Summary

11 total trials
2
Phase 1
1
Phase 2
6
Phase 3
1
Phase 4
Recruiting: 1Completed: 8Active: 1Terminated: 1

Active Trials (2)

Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD
NCT06637657Acute Coronary Syndrome
Recruiting
Enrollment: 5,586 participants
EPA for Metastasis Trial 2
NCT03428477Liver Metastasis
Phase 3Active
Enrollment: 418 participants

Key Facts

Market Cap$240.1M
Employees80 (-71% YoY)
CEOAaron D. Berg
IPO DateApr 1, 1993
Beta0.79
52-Week Range$11.25 – $17.31
Avg Volume70,305
ExchangeNASDAQ

Ownership

Float101.0%
Shares Outstanding20.7M

Recent Insider Trades

Fishman Peter L.OPTION EX.
Aug 1, 2026313 shares
Fishman Peter L.TAX W/H
Aug 1, 2026155 shares @ $14.26
Fishman Peter L.AWARD
Aug 1, 2026313 shares
Fishman Peter L.OPTION EX.
Jul 1, 20262,447 shares
Fishman Peter L.TAX W/H
Jul 1, 20261,206 shares @ $15.94

Peers

ACIUAC Immune S.A.
$227.0M
ALTAltimmune, Inc.
$404.6M
ANROAlto Neuroscience, Inc.
$987.3M
CLLSCellectis S.A.
$107.8M
DBVTDBV Technologies S.A.
$250.0M
ENGNenGene Holdings Inc.
$117.3M
KRROKorro Bio, Inc.
$217.2M
LRMRLarimar Therapeutics, Inc.
$248.3M
Data last updated: Nov 9, 2026, 03:54 AM